Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q2 2022 · 10-Q
Revenue$242.60M$242.60M−39.0% vs Q2 2021 Net Income-$52.90M-$52.90MN/M vs Q2 2021 EPS Diluted-$1.06-$1.06N/M vs Q2 2021 Gross Profit$65,600,000−54.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flowderived-$15,600,000N/M Free Cash Flowderived-$47,700,000N/M Margins · derivedGross margin27.0%−9.3 pt vs Q2 2021
Operating margin-31.5%−33.2 pt vs Q2 2021
Net margin-21.8%−21.7 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 2, 2022 · 33 d after period end